Trial of IMO-8400 in Adult Patients With Dermatomyositis

NCT02612857 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatomyositis

Interventions

DRUG: IMO-8400 Dose Group 1
DRUG: IMO-8400 Dose Group 2
DRUG: Placebo

Sponsor

Idera Pharmaceuticals, Inc.